The Diagnostics Business Group serves as the core business of our company. We mainly develop, manufacture and market in vitro diagnostics for hospital laboratories and clinical test centers. As a pioneer of biochemical testing, Sekisui Medical has always played a leading role with regard to in vitro diagnostics for the biochemical sector. In particular, the originality of the core technologies we apply in the lipids field keeps us way ahead of our competitors. The reagents we have developed to directly measure HDL-C and LDL-C hold the top market share both in Japan and overseas.

In recent years we have also launched a new latex reagent created by combining diagnostics development techniques (LTIA method) with latex technology that is based upon microparticle technology.
Our product lineups focus on four key areas (biochemistry, blood coagulation, diabetes and infectious diseases), and we aim to win the top market share in each of these sectors. In addition, we are expanding our lineup of specialized analyzers in each key area. We offer a comprehensive system of diagnostics and analyzers to meet a wide range of customer needs.

The Tsukuba Plant in Ryugasaki, Ibaraki Prefecture was constructed in 1990 as a production facility for in vitro diagnostics. It is installed with a wide range of production lines to handle multiproduct manufacturing, and a new pharmaceutical production building was constructed in 2007 to boost productive capacity. In 2012 a logistics facility was built to ensure consistent product management, and was integrated into the plant organization as an SCM center whose function is to accept orders and handle distribution.
A quality control system is in place to maintain high product quality, and the Tsukuba Plant earned ISO9001certification in 2003 and ISO13485 certification in 2005. The plant aims to continuously reduce its impact on the environment, and acquired ISO14001 certification in 2011.